Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) is among the fundamentally strong penny stocks to invest in. Analysts at H.C. Wainwright have reiterated their Buy rating on Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) while maintaining a price target of $2, implying an upside of over 900%. This overwhelming optimism stems from the company’s comprehensive portfolio update just a few days ago.
While focusing on the clinical development of its leading candidate, NGC-Cap, Processa Pharmaceuticals, Inc. has also started to initiate an adaptive pivotal Phase 3 study for PCS499 to address underserved kidney areas based on preliminary positive results and FDA approval of surrogate endpoints. With such a vision in mind, there is no doubt the company can actually exceed analyst expectations.
A syringe filled with a biopharmaceutical drug product on a light blue background.
On top of that, Processa Pharmaceuticals, Inc. has entered into a binding term sheet with privately held Intact Therapeutics, enabling it to receive $454 million in milestone payments, a 12% royalty on future sales, and a 3.5% equity stake in Intact. The exclusivity of its PCS12852 prokinetic agent for gastroparesis and other gastrointestinal motility disorders positions PCSA well to lead the market.
Processa Pharmaceuticals, Inc. is a Maryland-based clinical-stage biopharmaceutical company that develops chemotherapy drugs to enhance the efficacy of cancer treatment. Incorporated in 2017, the company adopts a “Regulatory Science Approach” to more effectively lead its pipeline programs.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
